These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 7804633)

  • 1. Quality assurance and the drug development process: an FDA perspective.
    Leonard EM
    Qual Assur; 1994 Jun; 3(2):178-86. PubMed ID: 7804633
    [No Abstract]   [Full Text] [Related]  

  • 2. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 3. Pediatric drug development in anesthesiology: an FDA perspective.
    Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
    Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
    [No Abstract]   [Full Text] [Related]  

  • 4. Food and Drug Administration approval process for ophthalmic drugs in the US.
    Lloyd R; Harris J; Wadhwa S; Chambers W
    Curr Opin Ophthalmol; 2008 May; 19(3):190-4. PubMed ID: 18408492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of QC/QA in "paper" NDA submissions.
    Heilman RD; Jones L; Kapili LV; Zamora G
    Qual Assur; 1995 Jun; 4(2):151-3. PubMed ID: 8720160
    [No Abstract]   [Full Text] [Related]  

  • 6. Preparing for an FDA preapproval inspection.
    Blackmer RA
    Qual Assur; 1994 Dec; 3(4):389-403. PubMed ID: 7613749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From laboratory to medicine cabinet.
    Caring; 1992 Nov; 11(11):16-20. PubMed ID: 10121248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How are drugs approved? Part 3. The stages of drug development.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Mar; 46(3):17-20. PubMed ID: 18416270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the FDA in drug development: implications for improved access to new HIV/AIDS therapies. Testimony before the Subcommittee on Health and Environment-Committee on Commerce concerning FDA reform bill HR 3199.
    Cooper EC; Sanders S
    AIDS Patient Care STDS; 1996 Aug; 10(4):213-20. PubMed ID: 11361591
    [No Abstract]   [Full Text] [Related]  

  • 10. Delegations of authority and organization; Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1993 Apr; 58(61):17093-4. PubMed ID: 10125229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interview with Gary L. Yingling, J.D.
    Yingling GL
    Qual Manag Health Care; 1999; 7(3):45-7. PubMed ID: 10537462
    [No Abstract]   [Full Text] [Related]  

  • 12. The big gap at the FDA.
    Stipp D
    Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA restructures new product review centers.
    Bouchie A
    Nat Biotechnol; 2002 Oct; 20(10):960. PubMed ID: 12355100
    [No Abstract]   [Full Text] [Related]  

  • 14. Disqualification of a clinical investigator--FDA. Final rule.
    Fed Regist; 1997 Sep; 62(172):46875-6. PubMed ID: 10173286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 16. Perspectives. Approval process a moving target in FDA reform hearings.
    Rhein R
    Faulkner Grays Med Health; 1996 Feb; 50(8):suppl 1-4. PubMed ID: 10154482
    [No Abstract]   [Full Text] [Related]  

  • 17. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
    Shulman SR; Brown JS
    Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA state of affairs.
    Lepore P
    Qual Assur; 1993; 2(1-2):156-61. PubMed ID: 8156204
    [No Abstract]   [Full Text] [Related]  

  • 19. Government report critical of FDA blasted as misleading.
    Fox JL
    Nat Biotechnol; 2008 Jan; 26(1):7. PubMed ID: 18183001
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA consolidates review process for new pharmaceuticals.
    FDA Consum; 2002; 36(6):2. PubMed ID: 12523280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.